Table 1 Characteristics of included meta-analyses on Chinese herbal medicine for cancer palliative care.
First author and year of publication | Included study design | Search period | Cancer site (tumor stage) | No. of studies (No. of patients) | Nature of Chinese herbal medicine (CHM) interventions^ | Nature of control interventions | Outcomes reported |
|---|---|---|---|---|---|---|---|
Ma, 2004 | RCT or quasi-RCT | 2003 | NSCLC (TNM III–IV) | 10 (771) | CHM + chemotherapy (Cisplatin drugs) | Cisplatin drugs chemotherapy alone | QOL |
Liu,2009 | RCT | Sep. 2007 | CRC (NR) | 6 (334) | Jianpi CHM + chemotherapy | Chemotherapy alone | Chemotherapy related toxicity, including: leucopenia, nausea and vomiting, neurotoxicity |
Wu, 2009a | RCT | Jul. 2008 | NSCLC (TNM III–IV) | 19 (1380) | Aidi injection + NP chemotherapy | NP chemotherapy alone | chemotherapy related toxicity: leucopenia, nausea and vomiting |
Wu, 2009b | RCT | Feb. 2009 | Liver cancer (TNM III–IV) | 45 (3236) | CHM + TACE | TACE alone | Survival rate |
Zhu,2009 | RCT or quasi-RCT | Aug. 2008 | NSCLC (TNM III–IV) | 16 (1041) | KLT+ NP or MVP or GP chemotherapy | NP or MVP or GP chemotherapy alone | QOL |
Chen, 2010 | RCT | Oct. 2009 | NSCLC (NR) | 11 (796) | CHM+ MVP or NP chemotherapy | MVP or NP chemotherapy alone | Survival rate |
Dong, 2010a | RCT or quasi-RCT | NR | Various (NR) | 12 (1230) | Astragalus injection + chemotherapy | Chemotherapy alone | QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia |
Fu, 2010 | RCT | Oct. 2009 | Various (NR) | 24 (4150) | CHM + chemotherapy | Chemotherapy alone or Chemotherapy + placebo | Chemotherapy related toxicity: leucopenia, thrombocytopenia |
Guo, 2010 | RCT | 2009 | Liver cancer (NR) | 33 (2619) | CHM + TACE | TACE alone or TACE + placebo | QOL |
Zhou, 2010 | RCT | NR | Gastric cancer (NR) | 13 (877) | CHM + chemotherapy | Chemotherapy alone | Survival rate |
Dong, 2010b | RCT | Apr. 2010 | NSCLC (TNM III–IV) | 29 (2062) | SFI + platinum containing chemotherapy | Platinum containing chemotherapy alone | QOL, chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia and nausea and vomiting |
Cui, 2011 | RCT | Dec. 2010 | NSCLC (TNM III–IV) | 9 (584) | KS + NP chemotherapy | NP chemotherapy alone | QOL |
Ma, 2011a | RCT | Jun. 2010 | NSCLC (TNM III–IV) | 11 (752) | KS + NP chemotherapy | NP chemotherapy alone | QOL |
Ma, 2011b | RCT | Jun. 2010 | Liver cancer (NR) | 11 (NR) | KS + TACE | TACE alone | QOL, survival rate |
Wang, 2011 | RCT | Aug. 2010 | Gastric cancer (NR) | 4 (304) | KLT + chemotherapy | Chemotherapy alone | Survival rate |
Qiao, 2011 | RCT | Mar. 2010 | Nasopharyngeal cancer (TNM I–IV) | 9 (795) | Yiqi Yangyin and Qingre Huoxue decoction + radiotherapy | Radiotherapy alone | QOL, survival rate |
Zhuang, 2011 | RCT or qusai-RCT | Nov. 2010 | NSCLC (TNM III–IV) | 6 (416) | Kang Ai injection + TP | TP chemotherapy alone | QOL |
Guo, 2012 | RCT or quasi-RCT | Aug. 2011 | CRC (TNM IV) | 20 (1304) | CHM + chemotherapy or radiotherapy | Chemotherapy or radiotherapy alone | Survival rate, QOL |
Jin, 2012 | RCT | Oct. 2011 | Various (NR) | 5 (373) | Extract of Ganoderma lucidum (chemotherapy or radiotherapy) | Chemotherapy + placebo or chemotherapy alone or radiotherapy+ conventional care | QOL |
Yang, 2012 | RCT or quasi-RCT | 2006 | Lung cancer (NR) | 10 (853) | CHM* + chemotherapy or radiotherapy or both | Chemotherapy or radiotherapy or both. | Survival rate |
Qin, 2012 | RCT | Oct. 2011 | NSCLC (TNM III–IV) | 13 (972) | Kang Ai injection + paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy | Paclitaxel or gemcitabine or navelbin + platinum containing chemotherapy alone | QOL |
Cai, 2012 | RCT | 2011 | Gastric cancer (TNM I–IV) | 9 (NR) | SFI + chemotherapy | Chemotherapy alone | QOL |
Wang, 2012a | RCT or qusai-RCT | 2010 | CRC (NR) | 9 (518) | CHM + chemotherapy | Chemotherapy alone | QOL |
Li, 2012a | RCT or quasi-RCT | 2011 | CRC (NR) | 14 (1081) | CHM+ chemotherapy | Chemotherapy alone | Survival rate |
Li, 2012b | RCT | Aug. 2011 | Liver cancer (NR) | 47 (3854) | CHM + TACE | TACE alone | Survival rate, chemotherapy related toxicity: nausea and vomiting |
Liu, 2012 | RCT | 2011 | Breast cancer (NR) | 6 (NR) | KS + chemotherapy | Chemotherapy alone | QOL |
Fan, 2012 | RCT | Jun. 2011 | Breast cancer (TNM I–IV) | 6 (496) | KS + chemotherapy | Chemotherapy alone | QOL |
Ma, 2012 | RCT | Jun. 2010 | NSCLC (TNM III–IV) | 8 (696) | KS +TP chemotherapy | TP chemotherapy alone | QOL |
Shi, 2012 | RCT or quasi-RCT | 2010 | Gastric cancer (NR) | 21 (1178) | CHM + chemotherapy | Chemotherapy alone | Survival rate, Chemotherapy related toxicity: leucopenia, anemia, thrombocytopenia. |
Wang, 2012b | RCT | Jun. 2012 | Gastric cancer (TNM III–IV) | 44 (3088) | CHM + conventional care | Conventional care alone | QOL |
Rong, 2012 | RCT | Nov. 2011 | NSCLC (TNM III–IV) | 18 (1108) | CHM + Chemotherapy | Chemotherapy alone | Survival rate |
Wang, 2012c | RCT or qusai-RCT | Sep. 2011 | Various (NR) | 11 (618) | Xiaoaiping injection + chemotherapy | Chemotherapy alone | QOL |
Zhang, 2012 | RCT | Dec. 2011 | Various (TNM II–IV) | 16 (1539) | SFI + chemotherapy or radiotherapy | Chemotherapy or radiotherapy alone | QOL |
Xu, 2012 | RCT or qusai-RCT | NR | Cervical cancer (TNM II–IV) | 18 (1657) | CHM + radiotherapy or CHM + radiotherapy + conventional care | Radiotherapy alone or radiotherapy + conventional care | Survival rate |
Cheung, 2013 | RCT | Oct. 2012 | Liver cancer (TNM II–IV) | 67 (5211) | CHM + TACE | TACE alone | QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting |
Li, 2013 | RCT | Sep. 2012 | NSCLC (TNM III–IV) | 24 (NR) | CHM + chemotherapy | Chemotherapy alone | QOL, survival rate, Chemotherapy related toxicity: nausea and vomiting, leucopenia, anemia and thrombocytopenia. |
Xie, 2013 | RCT or quasi-RCT | Jan. 2013 | Gastric cancer (TNM III–IV) | 15 (1008) | Huachansu + chemotherapy | Chemotherapy alone | Survival rate |
Du, 2013 | RCT | 2012 | Esophageal cancer (NR) | 5 (NR) | KS + chemotherapy or radiotherapy | chemo or radiotherapy or (chemo + radiotherapy) alone | Survival rate |
Tian, 2013 | RCT | Nov. 2012 | NSCLC (NR) | 24 (1845) | CHM + chemotherapy or radiotherapy | chemotherapy alone or chemotherapy + radiotherapy | Survival rate |
Jiang, 2013 | RCT | 2013 | Liver cancer (NR) | 16 (1105) | CHM + TACE | TACE alone | Survival rate |
Liu, 2013 | RCT or quasi-RCT | 2012 | NSCLC (NR) | 6 (346) | Zilongjin (bailongpian) + chemotherapy | chemotherapy (GP, NP or MVP, MVP) alone | QOL |
Xu, 2013 | RCT | Oct. 2012 | Gastric cancer (NR) | 15 (NR) | CHM + Chemotherapy | Chemotherapy alone | Survival rate |
Xiao, 2013 | RCT | 2012 | NSCLC (NR) | 10 (588) | Xiaoaiping injection + platinum containing chemotherapy | Platinum containing chemotherapy alone | QOL |
Su, 2013 | RCT or quasi-RCT | Oct. 2012 | Various (NR) | 82 (NR) | KS + chemotherapy or radiotherapy | Chemotherapy or radiotherapy alone | Survival rate |
Yan, 2013 | RCT | Feb. 2012 | NSCLC (TNM III–IV) | 10 (687) | KLT+NP chemotherapy | NP chemotherapy alone | QOL |
Sheng, 2013 | RCT | 2011 | NSCLC (NR) | 38 (NR) | SFI + chemotherapy (GP or NP or TP or DP) | Chemotherapy (GP or NP or TP or DP) alone | QOL |
He, 2013 | RCT | Sep. 2012 | NSCLC (TNM III–IV) | 19 (1110) | Shenfu injection + platinum containing chemotherapy | Platinum containing chemotherapy alone | QOL |
Chen, 2014 | RCT | Dec. 2012 | CRC (TNM IV) | 13 (940) | CHM + FOLFOX 4 | FOLFOX4 alone | Survival rate, Chemotherapy related toxicity: neutropenia, nausea and vomiting, neurotoxicity, diarrhea, anemia, thrombocytopenia and stomatitis |
Xu, 2014 | RCT | Dec. 2012 | NSCLC (TNM III–IV) | 17 (1605) | KLT + chemotherapy | Chemotherapy alone | Chemotherapy related toxicity: nausea and vomiting, leucopenia |
Liu, 2014 | RCT | Jun. 2012 | CRC (TNM IV) | 13 (781) | CHM + chemotherapy | Chemotherapy alone | Survival rate |
Wang, 2014 | RCT | 2012 | Gastric cancer (TNM III–IV) | 10 (1020) | SFI+FOLFOX4 | FOLFOX4 alone | QOL |
